Pharmaceuticals

Edgewise Therapeutics’ EDG-7500 Emerges as New HCM Contender

A new HCM competitor emerged last week, after Edgewise Therapeutics’ EDG-7500 showed strong evidence of its safety and efficacy in a pair of early-stage trials.

  • EDG-7500 is an oral cardiac sarcomere modulator designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diastolic dysfunctions.
  • EDG-7500 is later to the HCM party than BMS’ Camzyos and Cytokinetics’ aficamten, but is differentiated by its potential to improve blood flow without sacrificing LVEF.

Edgewise tested EDG-7500 in a Phase 1 trial to confirm the drug’s side effects, and an early part of a Phase 2 trial to measure EDG-7500’s impact on key oHCM biomarkers – and both trials proved successful.

The Phase 1 trial randomized 48 healthy patients to receive single doses of EDG-7500 or a placebo (5mg – 300 mg), while giving 34 healthy patients ascending doses daily for 14 days (25 to 100 mg), finding that…

  • EDG-7500 was well tolerated, with no clinically meaningful changes in vital signs, clinical chemistry, hematology, or electrocardiograms.
  • The EDG-7500 groups also had no meaningful changes in LVEF, and none of the subjects experienced a decrease in LVEF <50%.
  • Adverse events were similar between the EDG-7500 and placebo groups.

In the CIRRUS-HCM Part A Phase 2 trial, patients with obstructive HCM received single doses of EDG-7500 (50, 100 or 200 mg), finding that…

  • Patients taking 100 or 200 mg showed a 67% average reduction in resting LVOT-G and a 55% average reduction in provokable (Valsalva) LVOT-G.
  • The 100 mg and 200mg patients also achieved 31% and 64% average reductions in NT-proBNP.
  • Gradient reductions were achieved without a meaningful change in LVEF, and EDG-7500 proved to be well tolerated across all doses.

These results support Edgewise’s hypothesis that EDG-7500 can reduce LVOT gradients without reducing LVEF levels, potentially giving it a unique advantage over the current HCM frontrunners.

  • Wall Street certainly seemed to agree, driving a 55% surge in Edgewise’s stock price to a three year high of $29.

That added value should come in handy for Edgewise, which is still planning a lot more research on EDG-7500’s safety, efficacy, and treatment dosages for both oHCM and nHCM.

The Takeaway

Edgewise has a long way to go, but this safety and efficacy evidence, and EDG-7500’s potential to reduce LVOT gradients without compromising LVEF could make it a future HCM contender.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!